Current treatment of in-stent restenosis

F Alfonso, RA Byrne, F Rivero, A Kastrati - Journal of the American College …, 2014 - jacc.org
Management of patients with in-stent restenosis (ISR) remains an important clinical problem.
Although drug-eluting stents (DES) have drastically reduced the incidence of ISR, treatment …

Drug eluting stents: developments and current status

W Khan, S Farah, AJ Domb - Journal of controlled release, 2012 - Elsevier
Coronary stenting has revolutionized current perspective of coronary artery disease
management. Bare-metal stents (BMS) were introduced in 1994, but long-term results have …

Poly (L-lactide)/polycaprolactone based multifunctional coating to deliver paclitaxel/VEGF and control the degradation rate of magnesium alloy stent

U Farwa, HY Lee, H Lim, I Park, S Park… - International Journal of …, 2023 - Elsevier
Despite significant advancements made in cardiovascular stents, restenosis, thrombosis,
biocompatibility, and clinical complications remain a matter of concern. Herein, we report a …

[HTML][HTML] Diagnosis and management challenges of in-stent restenosis in coronary arteries

MC Alraies, F Darmoch, R Tummala… - World journal of …, 2017 - ncbi.nlm.nih.gov
Over the course of the 3 decades, percutaneous coronary intervention (PCI) with stent
implantation transformed the practice of cardiology. PCI with stenting is currently the most …

[HTML][HTML] The prevention of restenosis in vivo with a VEGF gene and paclitaxel co-eluting stent

J Yang, Y Zeng, C Zhang, YX Chen, Z Yang, Y Li… - Biomaterials, 2013 - Elsevier
Long-term clinical studies of drug-eluting stents (DES) have reported high incidence of late
thrombosis. Given the growing concern over the clinical application of this technology, we …

[PDF][PDF] Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients

PW Radke, M Joner, A Joost, RA Byrne… - …, 2011 - researchgate.net
Aims: The vascular effects of drug-eluting balloon (DEB) deployment in the absence of
coronary stents have not been characterised. This study evaluated potential vascular effects …

Current management of in-stent restenosis

AY Her, ES Shin - Korean circulation journal, 2018 - synapse.koreamed.org
Despite the advent of the drug-eluting stents (DES) and improved stent design, in-stent
restenosis (ISR) remains a challenging problem. The currently available options for …

In-stent restenosis.

MS Lee, G Banka - Interventional cardiology clinics, 2016 - europepmc.org
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. The mean time
from percutaneous coronary intervention (PCI) to ISR was 12 months with drug-eluting …

Vascular restoration therapy and bioresorbable vascular scaffold

Y Wang, X Zhang - Regenerative Biomaterials, 2014 - academic.oup.com
This article describes the evolution of minimally invasive intervention technologies for
vascular restoration therapy from early-stage balloon angioplasty in 1970s, metallic bare …

Refractory in-stent restenosis: Improving outcomes by standardizing our approach

R Waksman, M Iantorno - Current Cardiology Reports, 2018 - Springer
Abstract Purpose of Review This review will focus on our approach for the treatment of
refractory in-stent restenosis. Recent Findings The discovery of bare metal stents over three …